万孚生物将交上市以来最差成绩单

Core Viewpoint - Wanfu Bio is expected to report its worst performance since its IPO in 2015, with a projected net profit of 46 million to 69 million yuan for 2025, representing a year-on-year decline of 87.71% to 91.81% [1] Group 1: Financial Performance - The company anticipates a non-net profit of -7.5 million to -15 million yuan for 2025, marking its first-ever loss in this category since going public [2] - The decline in main business revenue is attributed to a drop in domestic income, influenced by VAT rate adjustments and policy impacts on hospital business, leading to pressure on both volume and price [2] - Factors contributing to the decline in net profit include price reductions in the domestic market, changes in product structure, a decrease in consolidated gross margin, high R&D and sales expenses, and impairment losses from divesting non-core, low-profitability businesses [2] Group 2: Market Performance - Despite domestic market challenges, Wanfu Bio has seen stable growth in overseas markets, particularly in North America, where a long-term supply agreement for respiratory products has been established [3] - The company's stock price has underperformed, with a cumulative decline of 9.15% in 2025, compared to a 29.87% increase in the overall market, and a drop of over 70% from its peak in 2020 [3][4] Group 3: Strategic Initiatives - To reverse the declining performance and stock price, the company is focusing on product specialization, cost control, channel upgrades, accelerated overseas expansion, governance optimization, and market value management [4] - The company has decided to postpone the implementation of the "Knowledge City Production Base Construction Project" to avoid resource waste and improve the efficiency of fundraising, given the significant changes in the internal and external operating environment [4] Group 4: Future Outlook - For 2026, the company plans to leverage market recovery in the domestic sector, focusing on core product lines to improve revenue, while continuing to expand in overseas markets [5] - The company aims to commercialize AI applications in pathology and clinical diagnostics, and to enhance its business from point-of-care (POC) to in vitro diagnostics (IVD), accelerating its international expansion [5]